BCM
ABVX

Bronte Capital Management’s Abivax ABVX Stock Holding History

Bronte Capital Management’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-156,747
Closed -$14.9M – 45
2025
Q3 		$14.9M Buy
+156,747
New +$9.61M 1.34% 19

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Bronte Capital Management's ABVX Position: Q4 2025 in Review

Bronte Capital Management sold out of Abivax (ABVX) in Q4 2025, closing a stake of 156,747 shares — an estimated $14.9M sold.

Bronte Capital Management first reported a position in ABVX in Q3 2025 and held it in 1 quarter. The position peaked at $14.9M in Q3 2025. 247 funds tracked by Wall St. Rank hold ABVX as of Q4 2025.

  • Bronte Capital Management reported no remaining Abivax position as of Q4 2025 after selling out during the quarter.
  • Bronte Capital Management sold 156,747 Abivax shares in Q4 2025, an estimated $14.9M.
  • Bronte Capital Management first reported a position in Abivax in Q3 2025 and held it in 1 quarter.
  • Bronte Capital Management's Abivax position peaked at $14.9M in Q3 2025.
  • 247 funds tracked by Wall St. Rank held Abivax as of Q4 2025.

Based on Bronte Capital Management's 13F filing for Q4 2025, filed 3 Feb 2026.